Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR‐T cell infusion

KEY CLINICAL MESSAGE: The prognosis of patients with relapsed or refractory (R/R) BL is poor with limited response to salvage therapy, especially for patients with early relapse (<6 months) or refractory disease. Novel therapies may be promising but need refinement. ABSTRACT: The prognosis of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Geerts, Paulus A. F., ’t Hart, Nils, Visser, Otto, Ortiz‐Maldonado, Valentín, Chamuleau, Martine E. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227197/
https://www.ncbi.nlm.nih.gov/pubmed/37260617
http://dx.doi.org/10.1002/ccr3.7361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227197/
https://www.ncbi.nlm.nih.gov/pubmed/37260617
http://dx.doi.org/10.1002/ccr3.7361

Ejemplares similares